BioCardia (NASDAQ:BCDA) Director Simon Stertzer Purchases 39,000 Shares

BioCardia, Inc. (NASDAQ:BCDA) Director Simon Stertzer acquired 39,000 shares of the company’s stock in a transaction on Tuesday, June 23rd. The stock was acquired at an average price of $1.00 per share, for a total transaction of $39,000.00. Following the purchase, the director directly owned 166,338 shares of the company’s stock, valued at approximately $166,338. This trade represents a 30.63% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

BioCardia Stock Up 6.0%

BCDA opened at $1.06 on Thursday. BioCardia, Inc. has a 12-month low of $0.78 and a 12-month high of $2.45. The business has a 50 day moving average of $1.02 and a 200-day moving average of $1.17. The stock has a market cap of $12.06 million, a price-to-earnings ratio of -1.16 and a beta of 0.51.

BioCardia (NASDAQ:BCDA) last posted its earnings results on Friday, May 15th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04). As a group, analysts expect that BioCardia, Inc. will post -0.76 earnings per share for the current year.

Institutional Trading of BioCardia

Several institutional investors have recently added to or reduced their stakes in BCDA. Cetera Investment Advisers bought a new stake in BioCardia in the 2nd quarter valued at $40,000. Geode Capital Management LLC increased its position in BioCardia by 70.4% during the 4th quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock worth $83,000 after buying an additional 27,263 shares during the period. Finally, DRW Securities LLC acquired a new stake in shares of BioCardia during the fourth quarter worth $72,000. 20.57% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of BioCardia in a research report on Tuesday, June 9th. Weiss Ratings reiterated a “sell (e+)” rating on shares of BioCardia in a research note on Monday, April 20th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $25.00.

About BioCardia

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.